Lead Product(s) : Carisbamate
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
SK life Science Initiates Phase 3 Clinical Trial of Carisbamate for Lennox-Gastaut Syndrome
Details : Phase 3 clinical trial initiated to evaluate the efficacy and safety of YKP509 (carisbamate) for the treatment of seizures associated with LGS. Carisbamate has also received orphan drug designation from the FDA.
Brand Name : YKP509
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 06, 2022
Lead Product(s) : Carisbamate
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?